Lex CommentaryLex Commentary
AMGN—
$0.00
BIIB—
$0.00
GILD—
$0.00
REGN—
$0.00
VRTX—
$0.00
MRNA—
$0.00
BNTX—
$0.00
ILMN—
$0.00
SNY—
$0.00
VTRS—
$0.00
ALNY—
$0.00
ARGX—
$0.00
BMRN—
$0.00
ACAD—
$0.00
ALKS—
$0.00
EXEL—
$0.00
HALO—
$0.00
INCY—
$0.00
INSM—
$0.00
IONS—
$0.00
JAZZ—
$0.00
NBIX—
$0.00
NVAX—
$0.00
NVCR—
$0.00
PTCT—
$0.00
RARE—
$0.00
RPRX—
$0.00
SRPT—
$0.00
UTHR—
$0.00
PACB—
$0.00
BBIO—
$0.00
ARVN—
$0.00
BEAM—
$0.00
CRSP—
$0.00
EDIT—
$0.00
NTLA—
$0.00
RXRX—
$0.00
SMMT—
$0.00
MDGL—
$0.00
AXSM—
$0.00
AUPH—
$0.00
ADPT—
$0.00
AGIO—
$0.00
ALLO—
$0.00
ARCT—
$0.00
ARWR—
$0.00
BCRX—
$0.00
CYTK—
$0.00
DNLI—
$0.00
ENTA—
$0.00
ERAS—
$0.00
FTRE—
$0.00
GMAB—
$0.00
GERN—
$0.00
GRFS—
$0.00
GH—
$0.00
IDYA—
$0.00
IMCR—
$0.00
IMVT—
$0.00
IOVA—
$0.00
JANX—
$0.00
KYMR—
$0.00
KRYS—
$0.00
KNSA—
$0.00
LENZ—
$0.00
LGND—
$0.00
LYEL—
$0.00
MEDP—
$0.00
MIRM—
$0.00
NGNE—
$0.00
ORIC—
$0.00
PCRX—
$0.00
PRAX—
$0.00
PTGX—
$0.00
RVMD—
$0.00
RYTM—
$0.00
RCKT—
$0.00
ROIV—
$0.00
SANA—
$0.00
SRRK—
$0.00
SIGA—
$0.00
STOK—
$0.00
GPCR—
$0.00
SUPN—
$0.00
TARS—
$0.00
TSHA—
$0.00
TVTX—
$0.00
TYRA—
$0.00
QURE—
$0.00
VERA—
$0.00
VCEL—
$0.00
VIR—
$0.00
WVE—
$0.00
XNCR—
$0.00
XENE—
$0.00
ZLAB—
$0.00
ZYME—
$0.00
KROS—
$0.00
REPL—
$0.00
RGNX—
$0.00
SPRY—
$0.00
ADMA—
$0.00
AMLX—
$0.00
AMPH—
$0.00
ASND—
$0.00
SEPN—
$0.00
TBPH—
$0.00
TRVI—
$0.00
HRMY—
$0.00
PCVX—
$0.00
MNKD—
$0.00
AMGN—
$0.00
BIIB—
$0.00
GILD—
$0.00
REGN—
$0.00
VRTX—
$0.00
MRNA—
$0.00
BNTX—
$0.00
ILMN—
$0.00
SNY—
$0.00
VTRS—
$0.00
ALNY—
$0.00
ARGX—
$0.00
BMRN—
$0.00
ACAD—
$0.00
ALKS—
$0.00
EXEL—
$0.00
HALO—
$0.00
INCY—
$0.00
INSM—
$0.00
IONS—
$0.00
JAZZ—
$0.00
NBIX—
$0.00
NVAX—
$0.00
NVCR—
$0.00
PTCT—
$0.00
RARE—
$0.00
RPRX—
$0.00
SRPT—
$0.00
UTHR—
$0.00
PACB—
$0.00
BBIO—
$0.00
ARVN—
$0.00
BEAM—
$0.00
CRSP—
$0.00
EDIT—
$0.00
NTLA—
$0.00
RXRX—
$0.00
SMMT—
$0.00
MDGL—
$0.00
AXSM—
$0.00
AUPH—
$0.00
ADPT—
$0.00
AGIO—
$0.00
ALLO—
$0.00
ARCT—
$0.00
ARWR—
$0.00
BCRX—
$0.00
CYTK—
$0.00
DNLI—
$0.00
ENTA—
$0.00
ERAS—
$0.00
FTRE—
$0.00
GMAB—
$0.00
GERN—
$0.00
GRFS—
$0.00
GH—
$0.00
IDYA—
$0.00
IMCR—
$0.00
IMVT—
$0.00
IOVA—
$0.00
JANX—
$0.00
KYMR—
$0.00
KRYS—
$0.00
KNSA—
$0.00
LENZ—
$0.00
LGND—
$0.00
LYEL—
$0.00
MEDP—
$0.00
MIRM—
$0.00
NGNE—
$0.00
ORIC—
$0.00
PCRX—
$0.00
PRAX—
$0.00
PTGX—
$0.00
RVMD—
$0.00
RYTM—
$0.00
RCKT—
$0.00
ROIV—
$0.00
SANA—
$0.00
SRRK—
$0.00
SIGA—
$0.00
STOK—
$0.00
GPCR—
$0.00
SUPN—
$0.00
TARS—
$0.00
TSHA—
$0.00
TVTX—
$0.00
TYRA—
$0.00
QURE—
$0.00
VERA—
$0.00
VCEL—
$0.00
VIR—
$0.00
WVE—
$0.00
XNCR—
$0.00
XENE—
$0.00
ZLAB—
$0.00
ZYME—
$0.00
KROS—
$0.00
REPL—
$0.00
RGNX—
$0.00
SPRY—
$0.00
ADMA—
$0.00
AMLX—
$0.00
AMPH—
$0.00
ASND—
$0.00
SEPN—
$0.00
TBPH—
$0.00
TRVI—
$0.00
HRMY—
$0.00
PCVX—
$0.00
MNKD—
$0.00

Geopolitics

Trade, tariffs, US-China competition and supply-chain security in pharmaceuticals.

AllCommentaryEquitiesPolicyGeopolitics
BioNTech (BNTX) inaugurates Australian mRNA facility ahead of 2027 readiness
Geopolitics

BioNTech (BNTX) inaugurates Australian mRNA facility ahead of 2027 readiness

Editorial Team21 October 2026 · 3 min
Asieris (SSE: 688176) Signs Theramex Deal for Cervical Precancer Treatment Cevira
Geopolitics

Asieris (SSE: 688176) Signs Theramex Deal for Cervical Precancer Treatment Cevira

Editorial Team8 October 2026 · 3 min
Bio-Techne (NASDAQ: TECH) Opens Bristol Manufacturing Site for Cell Therapy Materials
Geopolitics

Bio-Techne (NASDAQ: TECH) Opens Bristol Manufacturing Site for Cell Therapy Materials

Editorial Team8 October 2026 · 3 min
Asahi Kasei (TSE: 3407) Begins Patient Study of Antiviral Candidate AIC468
Geopolitics

Asahi Kasei (TSE: 3407) Begins Patient Study of Antiviral Candidate AIC468

Editorial Team8 October 2026 · 3 min
Biohaven (NYSE: BHVN) Licenses Asian IgG Degrader Rights to Ono (TSE: 4528)
Geopolitics

Biohaven (NYSE: BHVN) Licenses Asian IgG Degrader Rights to Ono (TSE: 4528)

Editorial Team8 October 2026 · 3 min
Orion (NASDAQ HELSINKI: ORNBV) Signs Qilu Deal for European Pembrolizumab Biosimilar
Geopolitics

Orion (NASDAQ HELSINKI: ORNBV) Signs Qilu Deal for European Pembrolizumab Biosimilar

Editorial Team6 October 2026 · 3 min
ORIC Pharmaceuticals (NASDAQ: ORIC) Hands Early CIP2A Development to Cancer Research UK
Geopolitics

ORIC Pharmaceuticals (NASDAQ: ORIC) Hands Early CIP2A Development to Cancer Research UK

Editorial Team6 October 2026 · 3 min
AstraZeneca (LSE: AZN) Opens Kendall Square Research Centre as US Investment Takes Shape
Geopolitics

AstraZeneca (LSE: AZN) Opens Kendall Square Research Centre as US Investment Takes Shape

Editorial Team5 October 2026 · 3 min
Orano Med (Unlisted) Opens French Lead-212 Manufacturing Facility
Geopolitics

Orano Med (Unlisted) Opens French Lead-212 Manufacturing Facility

Editorial Team3 October 2026 · 3 min
JCR Pharmaceuticals (TSE: 4552) Signs Italfarmaco Agreement for Hunter Syndrome Therapy
Geopolitics

JCR Pharmaceuticals (TSE: 4552) Signs Italfarmaco Agreement for Hunter Syndrome Therapy

Editorial Team2 October 2026 · 3 min
Teva (NYSE: TEVA) Broadens Its Samsung Bioepis Biosimilar Partnership
Geopolitics

Teva (NYSE: TEVA) Broadens Its Samsung Bioepis Biosimilar Partnership

Editorial Team2 October 2026 · 3 min
Bayer (Xetra: BAYN) Plans $2.2 Billion Pharmaceutical Campus in Ohio
Geopolitics

Bayer (Xetra: BAYN) Plans $2.2 Billion Pharmaceutical Campus in Ohio

Editorial Team2 October 2026 · 3 min
Novartis (NYSE: NVS) Pays $575 Million Upfront for Abogen's Autoimmune Programme
Geopolitics

Novartis (NYSE: NVS) Pays $575 Million Upfront for Abogen's Autoimmune Programme

Editorial Team2 October 2026 · 3 min
Eli Lilly (NYSE: LLY) CEO Highlights India's Biotech Funding Gap
Geopolitics

Eli Lilly (NYSE: LLY) CEO Highlights India's Biotech Funding Gap

Editorial Team2 October 2026 · 3 min
Hansoh Pharma (HKEX: 3692) Reports Phase III Weight-Loss Data for Olatorepatide
Geopolitics

Hansoh Pharma (HKEX: 3692) Reports Phase III Weight-Loss Data for Olatorepatide

Editorial Team2 October 2026 · 3 min
Asahi Kasei (TSE: 3407) Unifies Its Pharmaceutical Businesses Under One Brand
Geopolitics

Asahi Kasei (TSE: 3407) Unifies Its Pharmaceutical Businesses Under One Brand

Editorial Team1 October 2026 · 3 min
Hansoh Pharma (HKEX: 3692) Loses EU Approval After AstraZeneca (LSE: AZN) Challenge
Geopolitics

Hansoh Pharma (HKEX: 3692) Loses EU Approval After AstraZeneca (LSE: AZN) Challenge

Editorial Team30 September 2026 · 3 min
Vetter Expands Filling Capacity in Stages
Geopolitics

Vetter Expands Filling Capacity in Stages

Editorial Team29 September 2026 · 3 min
Pharmaceutical Tariff Exemptions Turn Product Definitions Into Strategy
Geopolitics

Pharmaceutical Tariff Exemptions Turn Product Definitions Into Strategy

Editorial Team29 September 2026 · 3 min
Novo's Hengrui Deal Targets the Weekly Obesity Pill
Geopolitics

Novo's Hengrui Deal Targets the Weekly Obesity Pill

Editorial Team29 September 2026 · 3 min
Lilly Sets a Long Horizon for Closing the GLP-1 Access Gap
Geopolitics

Lilly Sets a Long Horizon for Closing the GLP-1 Access Gap

Editorial Team28 September 2026 · 3 min
BioNTech's Failed Site Sale Exposes the Cost of Excess Capacity
Geopolitics

BioNTech's Failed Site Sale Exposes the Cost of Excess Capacity

Editorial Team28 September 2026 · 3 min
Merck Pays Upfront for Another Chinese Oncology Prospect
Geopolitics

Merck Pays Upfront for Another Chinese Oncology Prospect

Editorial Team28 September 2026 · 3 min
Sun Pharma Licences Cholesterol Drug for International Expansion
Geopolitics

Sun Pharma Licences Cholesterol Drug for International Expansion

Editorial Team28 September 2026 · 3 min
China Licensing Dispute Puts Adviser Conflicts in Focus
Geopolitics

China Licensing Dispute Puts Adviser Conflicts in Focus

Editorial Team27 September 2026 · 3 min
Boehringer's Shanghai Manufacturing Sale Shows a Different Side of China
Geopolitics

Boehringer's Shanghai Manufacturing Sale Shows a Different Side of China

Editorial Team24 September 2026 · 3 min
Henlius Turns to a US Partner for T-Cell Engagers
Geopolitics

Henlius Turns to a US Partner for T-Cell Engagers

Editorial Team24 September 2026 · 3 min
Lilly Commits $100 Million to an InnoCare Discovery Pact
Geopolitics

Lilly Commits $100 Million to an InnoCare Discovery Pact

Editorial Team24 September 2026 · 3 min
GSK Argues for an East–West Balance in Drug Sourcing
Geopolitics

GSK Argues for an East–West Balance in Drug Sourcing

Editorial Team23 September 2026 · 3 min
Nine Pharma Chairs Push Europe to Strengthen Its Innovation Base
Geopolitics

Nine Pharma Chairs Push Europe to Strengthen Its Innovation Base

Editorial Team22 September 2026 · 3 min
Novartis Adds a Chinese Radioligand Asset in a Deal Worth Up to $900 Million
Geopolitics

Novartis Adds a Chinese Radioligand Asset in a Deal Worth Up to $900 Million

Editorial Team22 September 2026 · 3 min
China's Radioligand Pipeline Attracts a Forecast, Not a Guaranteed Deal Boom
Geopolitics

China's Radioligand Pipeline Attracts a Forecast, Not a Guaranteed Deal Boom

Editorial Team21 September 2026 · 3 min
Washington May Keep the Door Open to Chinese Drug Licences
Geopolitics

Washington May Keep the Door Open to Chinese Drug Licences

Editorial Team18 September 2026 · 3 min
DPHARM: America's Trial Ambition Runs Into Site Capacity Constraints
Geopolitics

DPHARM: America's Trial Ambition Runs Into Site Capacity Constraints

Editorial Team18 September 2026 · 4 min
MaaT's PHOENIX Phase III Plan Sets a High Bar After the CHMP Negative Trend
Geopolitics

MaaT's PHOENIX Phase III Plan Sets a High Bar After the CHMP Negative Trend

Editorial Team18 September 2026 · 4 min
Bavarian Nordic's New CEO Tarja Stenvall Faces an Immediate Commercial Test
Geopolitics

Bavarian Nordic's New CEO Tarja Stenvall Faces an Immediate Commercial Test

Editorial Team17 September 2026 · 4 min
SK Bioscience and 1ST Biotherapeutics Form a Parkinson's Research Partnership
Geopolitics

SK Bioscience and 1ST Biotherapeutics Form a Parkinson's Research Partnership

Editorial Team17 September 2026 · 4 min
Japan's Approval of Xcopri Expands SK Biopharmaceuticals' Asian Footprint
Geopolitics

Japan's Approval of Xcopri Expands SK Biopharmaceuticals' Asian Footprint

Editorial Team16 September 2026 · 4 min
Türkiye's Push Into Rare-Disease Trials Reflects a Broader Emerging-Market Ambition
Geopolitics

Türkiye's Push Into Rare-Disease Trials Reflects a Broader Emerging-Market Ambition

Editorial Team15 September 2026 · 4 min
Gates' Measles Warning Puts Public Trust Into the Global Health Equation
Geopolitics

Gates' Measles Warning Puts Public Trust Into the Global Health Equation

Editorial Team15 September 2026 · 4 min
GSK Adds a Chinese T-Cell Programme in Deal Worth Up to $750 Million
Geopolitics

GSK Adds a Chinese T-Cell Programme in Deal Worth Up to $750 Million

Editorial Team15 September 2026 · 4 min
GSK's Dresden Closure Plan Exposes the Economics of Vaccine Capacity
Geopolitics

GSK's Dresden Closure Plan Exposes the Economics of Vaccine Capacity

Editorial Team14 September 2026 · 4 min
Singapore's Boston Office Makes Biotech Diplomacy More Practical
Geopolitics

Singapore's Boston Office Makes Biotech Diplomacy More Practical

Editorial Team11 September 2026 · 4 min
Samsung's $262 Million Deal Shows Why Drug Manufacturing Remains Global
Geopolitics

Samsung's $262 Million Deal Shows Why Drug Manufacturing Remains Global

Editorial Team11 September 2026 · 4 min
China's Obesity Pipeline Changes the Global Contest
Geopolitics

China's Obesity Pipeline Changes the Global Contest

Editorial Team11 September 2026 · 4 min
Drug Launch Order Becomes a Geopolitical Choice
Geopolitics

Drug Launch Order Becomes a Geopolitical Choice

Editorial Team10 September 2026 · 4 min
South Korea Gains Attention in Biotech Diversification
Geopolitics

South Korea Gains Attention in Biotech Diversification

Editorial Team9 September 2026 · 4 min
Washington's Drug Deals Reach Beyond Pricing
Geopolitics

Washington's Drug Deals Reach Beyond Pricing

Editorial Team7 September 2026 · 4 min
GSK's China Strategy Is Written in Its Deals
Geopolitics

GSK's China Strategy Is Written in Its Deals

Editorial Team5 September 2026 · 4 min

Real-time commentary on markets, companies, policy, geopolitics, and investor sentiment.

Join investors and analysts.